latest news releases from the newsroom
Tikvah Therapeutics, Inc.
Tikvah Therapeutics Names Nathan Andrew Shapira, M.D., Ph.D. Executive Director of Clinical Research and Development and Deputy Chief Medical Officer
ATLANTA, Aug. 2, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the appointment of Nathan Andrew Shapira, M.D., Ph.D. as Executive Director of Clinical Research and Development and Deputy Chief Medical Officer. Dr. Shapira will help to lead teams of researchers in the design, development, and execution of clinical development programs for Tikvah Therapeutics' neurological and psychiatric pharmaceutical products.
Baldwin & Lyons, Inc.
Baldwin & Lyons Announces Record Operating and Net Income for Quarter and Six Months
INDIANAPOLIS, Aug. 2, 2007 (PRIME NEWSWIRE) -- Baldwin & Lyons, Inc. (Nasdaq:BWINA) (Nasdaq:BWINB) today announced record quarterly operating income, defined as net income before investment gains or losses, of $9.1 million, or $.60 per share, compared to $6.2 million, or $.41 per share, reported in 2006. Net investment gains totaled $5.7 million, or $.38 per share, during the quarter and compare to losses of $.7 million, or $.05 per share in the prior year quarter. Including investment gains, second quarter net income was a record $14.8 million, or $.98 per share, compared to $5.4 million, or $.36 per share, for the second quarter of 2006.
Pride International, Inc.
Pride International, Inc. Reports 115 Percent Improvement in Second Quarter Net Income, Led by Strong Offshore Segment Performance
HOUSTON, Aug. 2, 2007 (PRIME NEWSWIRE) -- Pride International, Inc. (NYSE:PDE) today reported a 115% improvement in net income for the second quarter of 2007, to a record $146.1 million, or $0.83 per diluted share. The results compared to net income of $67.8 million, or $0.39 per diluted share, for the corresponding three months in 2006. Second quarter 2007 results included gains totaling $8.8 million, or $0.05 per diluted share, resulting primarily from the sale of a land rig located in Russia. Revenues for the second quarter of 2007 totaled $791.2 million, compared to revenues of $616.5 million during the second quarter of 2006.
Telvent GIT S.A.
Telvent Announces Second Quarter 2007 Earnings Conference Call
MADRID, Spain, Aug. 2, 2007 (PRIME NEWSWIRE) -- Telvent GIT, S.A. (Nasdaq:TLVT), the IT company for a sustainable and secure world, today announced the Company will release financial results for the second quarter ended June 30, 2007, after the close of trading on Thursday, August 30, 2007.